Efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated advanced thyroid carcinoma: Real world experience in 37 patients
Abstract
This study aimed to investigate the clinical efficacy and safety of dabrafenib plus trametinib for BRAFV600E-mutated advanced thyroid carcinoma in a Japanese real-world setting. We analyzed 37 BRAFV600E-mutated advanced thyroid carcinoma patients treated with dabrafenib plus trametinib between November 2023 and July 2025. Thirty-one patients (84%) had papillary thyroid carcinoma (PTC) histology, one (3%) had poorly differentiated thyroid carcinoma (PDTC) histology, and 5 (13%) had anaplastic thyroid carcinoma (ATC) histology. Among 31 PTC patients, dabrafenib plus trametinib was initiated as first-line treatment in 16 patients. The most common previous systemic therapy was lenvatinib (n = 16, 43%). The most common sites of target lesion were the lung (n = 23, 62%) and lymph node (n = 23, 62%). The median sum of the diameters of the target lesion was 40 mm (range, 8-166 mm). The objective response and disease control rates were 29% and 74% in patients with PTC, and 50% and 83% in patients with non-PTC (PDTC and ATC), respectively. The 12-month progression-free survival rates in patients with PTC and non-PTC (PDTC and ATC) were 73.2% (95% confidence interval [CI], 48.7-87.4%) and 60.0% (95% CI, 12.6-88.2%) (hazard ratio, 2.769; 95% CI, 0.691-11.1; p = 0.134), respectively. Dabrafenib plus trametinib treatment showed a response rate similar to that observed in clinical trials for BRAFV600E-mutated advanced thyroid carcinoma in this real-world study. However, long-term follow-up is required to determine the efficacy of dabrafenib plus trametinib treatment.
Related
- Successful Dabrafenib Plus Trametinib Treatment in a Patient with Braf V600e Mutation-Positive Mixed Invasive Mucinous and Nonmucinous Adenocarcinoma of the Lung: A Case Report
- Cobimetinib impairs tumor survival and immune escape by altering my-CAFs in BRAFV600E-mutated anaplastic thyroid carcinoma
- Clinical and Demographic Characteristics of Patients with Pulmonary Large-Cell Neuroendocrine Carcinoma: A Single-Center Experience
- Adherencia a la vigilancia del carcinoma hepatocelular y su asociación con el estadio tumoral al diagnóstico: experiencia de un hospital universitario Adherence to Hepatocellular Carcinoma Surveillance and Its Association with Tumor Stage at Diagnosis: Experience at a University Hospital
- BRAFV600E-Informed TI-RADS Reclassification of Biopsy Eligibility in Thyroid Nodules: A Retrospective Oracle Decision–Simulation Study
BibTeX
@article{yamazaki2026efficacy,
title = {{Efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated advanced thyroid carcinoma: Real world experience in 37 patients}},
author = {Haruhiko Yamazaki and Nobuyasu Suganuma and Mei Kadoya and Katsuhiko Masudo and Ai Matsui and Aya Saito},
journal = {Endocrine Journal},
year = {2026},
month = sep,
doi = {10.1507/endocrj.ej25-0629},
url = {https://www.jstage.jst.go.jp/article/endocrj/73/9/73_EJ25-0629/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated advanced thyroid carcinoma: Real world experience in 37 patients
AU - Haruhiko Yamazaki
AU - Nobuyasu Suganuma
AU - Mei Kadoya
AU - Katsuhiko Masudo
AU - Ai Matsui
AU - Aya Saito
PY - 2026
DA - 2026/09/01
JO - Endocrine Journal
DO - 10.1507/endocrj.ej25-0629
UR - https://www.jstage.jst.go.jp/article/endocrj/73/9/73_EJ25-0629/_article
AB - This study aimed to investigate the clinical efficacy and safety of dabrafenib plus trametinib for BRAFV600E-mutated advanced thyroid carcinoma in a Japanese real-world setting. We analyzed 37 BRAFV600E-mutated advanced thyroid carcinoma patients treated with dabrafenib plus trametinib between November 2023 and July 2025. Thirty-one patients (84%) had papillary thyroid carcinoma (PTC) histology, one (3%) had poorly differentiated thyroid carcinoma (PDTC) histology, and 5 (13%) had anaplastic thyroid carcinoma (ATC) histology. Among 31 PTC patients, dabrafenib plus trametinib was initiated as first-line treatment in 16 patients. The most common previous systemic therapy was lenvatinib (n = 16, 43%). The most common sites of target lesion were the lung (n = 23, 62%) and lymph node (n = 23, 62%). The median sum of the diameters of the target lesion was 40 mm (range, 8-166 mm). The objective response and disease control rates were 29% and 74% in patients with PTC, and 50% and 83% in patients with non-PTC (PDTC and ATC), respectively. The 12-month progression-free survival rates in patients with PTC and non-PTC (PDTC and ATC) were 73.2% (95% confidence interval [CI], 48.7-87.4%) and 60.0% (95% CI, 12.6-88.2%) (hazard ratio, 2.769; 95% CI, 0.691-11.1; p = 0.134), respectively. Dabrafenib plus trametinib treatment showed a response rate similar to that observed in clinical trials for BRAFV600E-mutated advanced thyroid carcinoma in this real-world study. However, long-term follow-up is required to determine the efficacy of dabrafenib plus trametinib treatment.
SN - 1348-4540
SN - 0918-8959
ER -